Thermo Fisher Scientific has partnered with Ortho Clinical Diagnostics to supply its MAS Quality Controls and LabLink xL Quality Assurance Software, to be used with the latter’s VITROS analysers.
As per the deal, Ortho Clinical’s users will gain full access to MAS third-party quality controls and the LabLink xL web-based quality assurance programme. This programme offers real-time quality control monitoring integrated with automatic data entry upload and audit-friendly reports.
Furthermore, the users can access features such as support, service and quality control ranges for certain reagent lots.
Thermo Fisher Scientific clinical diagnostics president Tina Liedtky said: “Our MAS Quality Control products help clinical laboratories maximise productivity with market-leading consolidation of control material, shelf-life stability longer than the industry standard and open vial stability that reduces the cost and time required for recalibrating new lots.”
Located on the UC Davis Sacramento campus, the facility will aid in targeted and untargeted metabolic profiling for broad population-based cohorts in translational research and precision medicine areas.
The Center will create regulated processes for the research community, which will include end-to-end metabolic profiling workflows and improved liquid chromatography-mass spectrometry (LC-MS) techniques.
Protocols needed for analytical controls to screen instrument performance and training courses for metabolomics employees, researchers and core lab managers will also be developed by the Center .
The alliance will use Thermo Fisher’s Orbitrap technology.
Levering the new generation of Orbitrap-based mass spectrometers integrated with the Thermo Scientific Vanquish Duo UHPLC system for high throughput, the centre aims to produce superior data.
Furthermore, the instrument integration will aid in creating simplified workflows required for large-scale studies and translational research.
Last month, Thermo Fisher launched its Ion AmpliSeq SARS-CoV-2 Insight Research Assay for early detection of emerging and known Covid-19 virus variants from samples with reduced lower viral loads.